Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Justin Hart

Plastic and Reconstructive Surgery Carmel, IN Doctor of Osteopathy

NPI 1942697313 CMS profile 1350538

13450 N Meridian St Ste 145, Carmel, IN 46032

Open in the dashboard

General payments

$5,654

89 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Justin Hart of Carmel, IN is reported in the CMS Open Payments database as having received $5,654 across 89 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $244 3
2023 General $260 2
2022 General $1,757 17
2021 General $942 18
2020 General $1,270 20
2019 General $1,180 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Justin Hart
  • Plastic and Reconstructive Surgery median
  • Middle half of Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to Justin Hart were reported at $244. Among 2,070 Plastic and Reconstructive Surgery profiles paid that year, the median was $442 and the middle half received between $150 and $1,242.

Show as a table
Year Justin Hart Plastic and Reconstructive Surgery median Middle half National median
2019 $1,180 $335 $121–$1,264 $163
2020 $1,270 $162 $57–$417 $114
2021 $942 $245 $89–$735 $132
2022 $1,757 $325 $120–$932 $149
2023 $260 $343 $129–$999 $160
2024 $0 $390 $141–$1,085 $164
2025 $244 $442 $150–$1,242 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AxoGen $1,138 13 payments
  2. Allergan Inc. $788 24 payments
  3. Integra LifeSciences Corporation $686 13 payments
  4. TELA Bio, Inc. $592 8 payments
  5. Sientra, Inc. $357 3 payments
  6. AbbVie, Inc. $260 2 payments
  7. Mentor Worldwide LLC $252 4 payments
  8. Motiva USA, LLC $244 3 payments
  9. Musculoskeletal Transplant Foundation Inc. $220 3 payments
  10. KLS-Martin L.P. $214 1 payment
  11. Other $903 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,654 89 payments
Products named General payments · program years 2019–2025
  1. Avance Nerve Graft $850 6 payments
  2. AxoGuard Nerve Connector $637 9 payments
  3. AXOGUARD NERVE PROTECTOR $637 9 payments
  4. NATRELLE $483 17 payments
  5. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $357 3 payments
  6. BILAYER WOUND MATRIX (BWM) $328 7 payments
  7. INTEGRA WOUND MATRIX (IWM) $328 7 payments
  8. IDRT $328 7 payments
  9. FLOWABLE $328 7 payments
  10. AMNIOEXCEL $307 5 payments
  11. Other $3,581 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

70

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$456

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

27.1%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ondansetron Odt Ondansetron Brand 19 $199
Cephalexin Generic 14 $114
Oxycodone Hcl Generic 22 $97
Ibuprofen Generic 15 $46

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$33,498

Medicare's payments for the services billed

Medicare patients

57

Average age 69

Services billed

188

44 women, 13 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 56%
Cancer 51%
Depression 35%
Chronic kidney disease 32%
Ischemic heart disease 30%
Osteoporosis 25%
Diabetes 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

89 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic and Reconstructive Surgery in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record